Vasopressin analog · water & bleeding
Desmopressin is a synthetic version of vasopressin, the pituitary hormone that tells the kidneys to hold on to water. Two changes to the molecule make it longer-acting and greatly reduce vasopressin's effect on blood vessels. It is used for central diabetes insipidus, childhood bedwetting, and bleeding in mild hemophilia A and type 1 von Willebrand disease.
Desmopressin activates vasopressin V2 receptors in the kidney, which lets more water move back into the blood and makes urine smaller in volume and more concentrated. That is why it can stand in for the missing hormone in central diabetes insipidus but does nothing in nephrogenic diabetes insipidus, where the kidney cannot respond. Compared with natural vasopressin, its altered first and eighth amino acids give a longer action and much weaker effects on blood vessels and gut muscle. Given into a vein, it also raises blood levels of clotting factor VIII within about half an hour, which supports clotting in people with mild deficiencies.
Desmopressin has been studied in people for decades. In 1977, infusions in patients with mild or moderate hemophilia and von Willebrand disease raised factor VIII activity two- to sixfold, and several patients had dental extractions and major operations without plasma concentrates, though two of the first four still needed them1.
A Cochrane review of 41 randomized trials in 2,760 children found fewer wet nights than placebo while it was being taken, but no lasting difference after it was stopped2. For adult nocturia, a systematic review of 10 trials (2,191 patients) found modest benefits, including fewer nighttime voids and roughly an extra hour before the first void, with hyponatremia and headache as the main harms3.
A meta-analysis in older adults using it for nocturia estimated a pooled incidence of low blood sodium of about 7.6%4.
The FDA first approved desmopressin as DDAVP in 1978, and current US tablets, injections, nasal sprays and an oral solution cover uses that include central diabetes insipidus, primary nocturnal enuresis, and bleeding in hemophilia A or type 1 von Willebrand disease5,6. Products approved specifically for adult nocturia, Noctiva and Nocdurna, are listed as discontinued.
The injection label carries a boxed warning for hyponatremia (low blood sodium), which can be severe and lead to seizures, coma, respiratory arrest or death5. It is contraindicated with excess fluid intake, loop diuretics, systemic or inhaled glucocorticoids, moderate-to-severe kidney impairment, or past hyponatremia. Other listed reactions include headache, nausea, abdominal cramps, flushing, local redness, swelling or burning pain, blood pressure changes, fluid retention, allergic reactions and clotting events; it may cause thrombosis in type 2B von Willebrand disease5.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.
Brand names on this page belong to their owners and are used only to identify a product. goodtides is not affiliated with those companies.